ABG Acquisition Corp. I
NASDAQ:ABGIABG Acquisition Corp. I does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ABG Acquisition Corp. I was incorporated in 2020 and is based in New York, New York.
Americas Technology Acquisition
NYSEARCA:ATAAmericas Technology Acquisition Corp. does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, recapitalization, reorganization, or similar business combination in the technology, media, and telecommunications sector. The company was incorporated in 2020 and is based in Dallas, Texas.
Biophytis
NASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
PLBY Group
NASDAQ:PLBYPLBY Group, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and internationally. It operates through three segments: Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. The company offers sexual wellness products, such as lingerie, bedroom accessories, intimacy products, and other adult products; style and apparel products for men and women; digital entertainment and lifestyle products; and beauty and grooming products for men and women, such as skincare, haircare, bath and body, grooming, cosmetics, and fragrance. It also owns and operates digital commerce retail platforms, such as playboy.com, honeybirdette.com, yandy.com, and loversstores.com; and Honey Birdette and Lovers retail stores. In addition, the company licenses Playboy name, Rabbit Head Design, and other trademarks and related properties; and programming content to cable television operators and direct-to-home satellite television operators. Further, the company business covers the subscription sale of playboyplus.com and playboy.tv, which are online content platforms. It offers its products under its flagship brand Playboy. PLBY Group, Inc. is headquartered in Los Angeles, California.
Vivos Therapeutics
NASDAQ:VVOSVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.